Product nameTeneligliptin, DPP-4 inhibitor
DescriptionPotent, long-lasting DPP-4 inhibitor
Potent, long-lasting DPP-4 (dipeptidylpeptidase-4) inhibitor. Competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro (IC50 = ~ 1 nM). Attenuates lipogenesis in the liver by activating AMPK and downregulating the expression of genes involved in lipogenesis. Improves metabolic abnormalities in a mouse model of postmenopausal obesity.
Storage instructionsShipped at 4°C. Store at -20°C. Store In the Dark. Store under desiccating conditions.
Soluble in water to 159.01 mM, in DMSO to 159.01 mM and in ethanol to 27.03 mM.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- Ideta T et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci 16:29207-18 (2015). Read more (PubMed: 26670228) »
- Sameshima A et al. Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. J Endocrinol 227:25-36 (2015). Read more (PubMed: 26264980) »
- Yoshida T et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 20:5705-19 (2012). Read more (PubMed: 22959556) »
- Fukuda-Tsuru S et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696:194-202 (2012). Read more (PubMed: 23022337) »